Author

Dong-Mei Yan

h-index 14 View on Semantic Scholar

We have 1 of 47 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

Third-generation anti-CD30 CAR T-cell therapy demonstrates high efficacy and a favorable safety profile in r/r CD30+ lymphoma patients and addition of auto-HSCT following CAR T-cell therapy improves depth of remission and potentially enhances OS and PFS.

Xiang-Min Wang, Qing Zhang, Dong-Mei Yan et al. · Clinical Cancer Research · 0 citations